Analysis Outlook Therapeutics Faces Two Make-or-Break July Deadlines Amid Nasdaq Fight and FDA Priority Review
The stock of Outlook Therapeutics has staged a remarkable recovery, gaining nearly 30% in a single week to close at $1.58. That puts the biotech name comfortably above the Nasdaq’s...